Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.04 CAD
Change Today 0.00 / 0.00%
Volume 0.0
KNE On Other Exchanges
As of 10:15 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

kane biotech inc (KNE) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/30/14 - C$0.12
52 Week Low
11/24/14 - C$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KANE BIOTECH INC (KNE)

Related News

No related news articles were found.

kane biotech inc (KNE) Related Businessweek News

No Related Businessweek News Found

kane biotech inc (KNE) Details

Kane Biotech Inc., a biotechnology company, is engaged in the development and commercialization of products to prevent and remove biofilms. Its products include DispersinB, an antibiofilm enzyme for the wound care market; Aledex for the medical device coating market; KBI antibacterial disinfectant; and StrixNB for the oral care market. The company was founded in 2001 and is based in Winnipeg, Canada.

Founded in 2001

kane biotech inc (KNE) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

kane biotech inc (KNE) Key Developments

Kane Biotech Signs on Joint Development Agreement with an Global Animal Health Company

Kane Biotech signed a joint development agreement with an undisclosed global animal health company. Initial revenue from the agreement is USD 100,000, which will be included in the firm's second quarter financial statements. Terms of the agreement are confidential.

Kane Biotech Inc. Announces Management Changes

Kane Biotech Inc. announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.

Kane Biotech Inc. Auditor Raises 'Going Concern' Doubt

Kane Biotech Inc. filed its Annual on Apr 07, 2015 for the period ending Dec 31, 2014. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KNE:CN C$0.04 CAD 0.00

KNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KNE.
View Industry Companies

Industry Analysis


Industry Average

Valuation KNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.3x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANE BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at